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Identification of polymorphic repeating units on DNA as a cause of many 
neurological disorders has introduced a new concept in molecular biology: Dynamic 
mutations. Many of the identified dynamic mutations involve expansion of tri-
nucleotide repeats within disease genes. Nine neurodegenerative disorders are 
currently known to be caused by expanding CAG trinucleotide repeats. These are 
Huntington’s Disease (HD), Dentato-Rubral Pallidoluysian Atrophy (DRPLA), 
Spinal and Bulbar Muscular Atrophy (SBMA), and Spinocerebellar Ataxia (SCA) 
Type 1, 2, 3, 6, 7 and 17. All are inherited in an autosomal dominant fashion except 
for SBMA, which is X-linked recessive. In all polyQ diseases, the disease mutation 
involves an increase in the number of CAG repeats within the coding regions of 
the respective genes. Since CAG triplets encode glutamine in the proteins, diseases 
caused by CAG repeat expansions are known as “Polyglutamine (polyQ ) Diseases”. 
PolyQ diseases share certain clinical, neuropathological and molecular findings. 
The most widely studied polyQ disease is HD. In HD and other polyQ diseases, con-
formational change in the mutant protein causes abnormal folding and proteolysis 
of the protein, leading to the formation of a toxic polyQ fragment, which aggregates 
and causes neuronal dysfunction and selective neuronal death in the brain.
Keywords: polyglutamine diseases, trinucleotide repeats, Huntington’s disease, CAG 
expansion, neuronal death
1. PolyQ diseases
1.1 Clinical and neuropathological characteristics of PolyQ diseases
Despite a wide spectrum of clinical presentations, all polyQ diseases are 
characterized by late onset and progressive neurodegeneration, involving selective 
neuron death. Clinical symptoms generally begin in midlife, although they can 
also manifest earlier. In all cases, age of onset is inversely related to the CAG repeat 
size in respective genes. Larger CAG repeat tracts were found to be associated with 
earlier disease onset, severe phenotype and rapid progression [1]. The expanded 
repeat tracts are prone to changes in length during intergenerational transmission. 
This results in earlier disease onset in the later generations, known as anticipation. 
Neurodegenerative Diseases - Molecular Mechanisms and Current Therapeutic Approaches
2
The pathology of polyQ diseases involves selective neuronal degeneration mostly 
in the central nervous system (CNS). PolyQ disease loci, polyQ proteins and repeat 
sizes are shown in Table 1, and the clinical and neuropathological characteristics 
of polyQ diseases are listed in Table 2 [2].
1.2 Genotype-phenotype correlations in polyQ diseases
CAG repeat sizes on polyQ alleles are generally categorized in three main 
groups, being normal, intermediate and pathogenic. Alleles with repeat numbers in 
the normal range are not associated with disease state. Intermediate alleles usually 
do not cause disease, but have a great tendency to increase in number upon vertical 
transmission and may cause disease in the next generation. Alleles having repeat 
numbers in the pathological range definitely cause the disease in a normal life span. 
Composition of the repeat tract is important in determining the disease state, as 
well as the size of the repeats. In SCA1 and SCA2, CAG repeat tracts on normal 
alleles are usually interrupted with other triplets, increasing the stability of DNA. 
However, disease alleles contain uninterrupted, pure CAG repeats. SCA1 normal 
alleles are almost always interrupted with one to three CAT repeats, and the disease 
causing expanded alleles consist of perfect CAG repeat tracts, with one reported 
exception of an expanded allele (58 repeats) interrupted by two CAT triplets [3]. 
Later onset of disease than expected in this patient suggests that the sequence 
composition of the repeat tract may be an important determinant in SCA1 disease 
manifestation. SCA2 normal alleles contain one to three CAA interruptions, with 
only two reported exceptions of pure 14 and 29 CAG repeats [4].
1.3 Mechanisms of polyQ pathogenesis
Although polyQ proteins are expressed widely in all cell and tissue types, each 
disease is characterized by selective neuron degeneration. The molecular mechanism of 
neurodegeneration is not clear yet, but the properties of mutant polyQ proteins provide 
important clues, and it is very likely that all the diseases in this group share similar 
mechanisms of pathogenesis. The very first effect of the repeat expansion mutation is 
proved to be the conformational change of the mutant protein. The new conformation 
of the mutant polyQ proteins was shown to confer a novel deleterious function [5]. 




HD 4p16 Huntingtin 348 6–35 29–39 36–250
DRPLA 12p13 Atrophin-1 190 3–35 _ 49–88
SBMA Xq11-q12 Androgen 
Receptor
99 11–34 _ 38–62
SCA 1 6p23 Ataxin-1 87 6–44 39–44 39–83
SCA 2 12q24.1 Ataxin-2 150 15–31 32–33 34–200
SCA 3 14q32.1 Ataxin-3 48 12–41 _ 55–84
SCA 6 19p13 α1A-Ca+2 
Channel
280 4–17 _ 20–33
SCA 7 3p14-21.1 Ataxin -7 96 4–35 28–35 37–306
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Mutant polyQ proteins are cleaved by proteases, aggregate, and form inclusions in the 
cells. The polyQ aggregates are ubiquitinated and recruite many proteins to the aggre-
gates, like transcription factors (TFs), chaperons, and proteasomes. The exact protein 
context could influence the differences in areas of neurodegeneration. Mutant proteins 
may lead to cell death by causing changes in protein interactions, transcriptional 
dysregulation and dysfunction of the ubiquitin proteasome system (UPP). On the 
other hand, it is also possible that partial loss of the normal functions of proteins may 
be contributing to disease pathogenesis [6]. So, gain and loss of function mechanisms 
could have convergent effects in polyQ-mediated neurotoxicity.
2. Huntington’s disease
2.1 Epidemiology and clinical correlates
The first definitive description of HD was presented in 1872 by Dr. George 
Huntington, in his article titled “On Chorea” [7]. This article pinpoints the important 
Disease Clinical findings Neuropathology
HD Involuntary choreic movements, cognitive and 
emotional disturbances, dementia
Cortex, basal ganglia and striatum
DRPLA Adults: ataxia, choreathetosis, dementia
Childhood: mental retardation, behavioral 
disturbances, myoclonus and epilepsy
Dentatorubral and pallidoluysian systems, 
basal ganglia, cerebellum
SBMA Walking disability, muscle cramps, decreased 
deep tendon reflexes, dysarthria and 
dysphagia, afixation, pneumonia
Anterior horn cells in spinal cord and 
dorsal ganglia
SCA 1 Universal gait and limb ataxia, dysarthria, 
nystagmus, mild optic atrophy, hypertonia 
(early), hypotonia (late), decreased deep 
tendon reflexes, dysphagia, difficulties in 
breathing, extrapyramidal findings
Purkinje cells, dentate inferior olive, 
cranial nerve nuclei, substantia nigra, 
putamen, pallidum, subthalamic nucleus
SCA 2 Near universal gait and limb ataxia, dysarthria, 
abnormal eye movements, neuropathy, chorea, 
dystonia, dementia
Purkinje cells, inferior olive, 
pontocerebellar nuclei, substantia nigra, 
striatum, Clarke’s column of the spinal 
cord, demyelination of posterior columns, 
cerebral cortex, spinocerebellar tracts
SCA3 Type 1: early onset, dystonia and rigidity
Type 2: cerebellar and pyramidal signs
Type 3: late onset, peripheral neuropathy, 
cerebellar signs
Type 4 : parkinsonism
Globus pallidus, subthalamic nucleus, 
substantia nigra, dentate nucleus, pontine 
and cranial nerve nuclei, spinal neurons, 
peripheral neuropathy
SCA 6 Ophtalmoplegia, spasticity, peripheral 
neuropathy, dysphagia, parkinsonism, balance 
problems
Loss of Purkinje and granular cells, neuron 
death in dentate nucleus and inferior olive, 
atrophy in brain stem
SCA 7 Visual loss, gait and limb ataxia, dysarthria, 
widespread pyramidal findings, decreased 
vibration sense, dysphagia, hearing 
impairment
Retina, cerebellar Purkinje and granule 
cells, dentate, inferior olive, subthalamic 
nucleus and spinal motor neurons
SCA 17 Gait and limb ataxia, dementia, parkinsonism, 
chorea or dystonia
Small neurons in caudate nucleus and 
putamen, Purkinje cells, thalamus, frontal 
and temporal cortex
Table 2. 
Clinical and neuropathological findings in PolyQ diseases.
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essential features of the disease; its hereditary course and its manifestation in adult life. 
This first full description of the disease awakened the HD research, and studies con-
cerning the origin and prevalence of the disease have started. It has been cleared that the 
gene originated in Northern Europe, with a prevalence of 5–10 affected people per 100 
000 among individuals of European descent. Apart from Finland, there is a uniform 
prevalence of HD throughout Europe. The prevalence of HD in Finland is lower than 
that of other Northern European countries, which can be partly explained by the lower 
frequency of htt haplogroup A on chromosome 4 among the Finnish population.
HD is a chronic and progressive neurodegenerative disorder of the CNS, inherited 
in an autosomal dominant manner. The characteristic clinical features include motor, 
cognitive and behavioural abnormalities. HD is regarded as an adult-onset disease since 
the first signs appear in the third to fifth decade of life. However, the age at onset (AO) 
follows a normal distribution, showing a peak around the fourth decade, with some 
patients manifesting the disease before 20 (Juvenile HD, 5–10 per cent of HD cases) 
or after 60 years of age (~20 per cent of HD cases). The illness lasts for about 15–20 
years. The clinical course of HD involve three basic abnormalities: Motor dysfunction, 
behavioural disturbances and cognitive decline. Motor abnormalities involve involun-
tary movements in the extremities and progress into jerky movements. The severity of 
involuntary movements, known as chorea, increases progressively during the initial 
years of the illness, and is later replaced by bradykinesia and rigidity. In the disease 
course, patients also develop dysarthria, dysphagia, balance problems, and incoordina-
tion. Later on rigidity dominates, which may leave the patient bed-bound or confined 
to a wheelchair. In juvenile HD (JHD) patients, rigidity is more common than chorea. 
Behavioural abnormalities usually precede the motor symptoms, including depression, 
anxiety, and changes in personality, however they are usually unnoticed. Suicide, the 
third most common cause of death among HD patients, is more common than in the 
general population. Through the late stages of HD, patients develop dementia, charac-
terized by inefficient use of memory and impairment of executive functions [8].
2.2 Neuropathology of HD
The neuropathology of HD is restricted to the brain, selective loss of neurons 
within the striatum being the predominant hallmark. Medium sized, spiny GABA-
ergic striatal output neurons are lost up to 80 per cent. Neuronal loss in HD patients 
begins early in life, before the manifestation of motor symptoms. At the time of motor 
onset of disease, cortical grey matter, subcortical white matter, and about 30 per 
cent of caudate neurons are already lost (Figure 1). These all account for loss of brain 
weight by 20 to 30 per cent less than normal [9]. The neuronal intranuclear inclusions 
(NII) found in the brain are accepted as a neuropathological marker of HD. Huntingtin 
inclusions were shown in the cortex and striatum of transgenic HD mice, and post-
mortem HD brains [10]. Gamma Amino Butyric Acid (GABA), acetylcholine and 
dopamine neurotransmitters were found to be decreased in the diseased basal ganglia. 
Also glutamic acid decarboxylase (GAD) levels, the enzyme involved in GABA biosyn-
thesis, is found to be reduced in the caudate, putamen and globus pallidus.
2.3 Molecular genetics of HD
2.3.1 The HD gene structure
In 1993, human HD gene was localized to chromosome 4p16.3 by positional clon-
ing approach [11]. The HD gene, called IT-15, consists of 67 exons spanning 180 kb 
of DNA (Figure 1). The (CAG)n repeat is located in Exon 1, 17 codons downstream 
the ATG start codon, and encodes a highly polymorphic and unstable segment of 
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glutamines. The repeat tract varies between 6–35 CAGs in healthy individuals and 
36–250 CAGs in HD patients. Adjacent to (CAG)n repeats, there is a stretch of pro-
line encoding CCG repeats, which is slightly polymorphic (6–12 repeats) and stably 
transmitted [12]. Most healthy chromosomes and the majority of mutant chro-
mosomes contain seven CCG repeats. In Exon 58, there is a rare codon-loss (GAG, 
glutamate) polymorphism (Δ2642), which occurs in 5% of healthy and 24–38% of 
HD chromosomes [13]. The human HD gene is highly conserved across a wide range 
of species like mouse, rat, fugu, zebrafish, and pig [3, 14, 15].
2.3.2 The HD mutation
The mutation causing HD is the expansion of the CAG repeat tract in the first 
exon of the HD gene [11]. Healthy chromosomes contain 6–35 CAGs, and HD 
chromosomes possess 36–250 units [16]. The CAG repeats in the HD gene are  
highly unstable, resulting in expansions or contractions upon transmission to  
the next generation. The CAG repeat tract was shown to be unstable in 80% of the 
transmissions. The size and direction of the instability depend on the sex of the 
affected parent. In maternal transmissions, nearly equal numbers of expansions 
and contractions are seen, and shifts range from one to three repeats in size. In 
contrast, paternal transmissions are more frequently expansions. In addition to 
meiotic instability, a modest degree of instability was shown within and between 
somatic tissues of HD patients. In the brain, instability was observed in the caudate 
and putamen; in non-CNS tissues, most instability was observed in the liver and 
kidney. Three general mechanisms can be proposed to account for repeat instability: 
Slippage during DNA replication, misalignment with subsequent excision repair, 
and unequal crossover and recombination. Slippage-mediated length change during 
DNA replication better explains the instability in repeat size in HD.
2.3.3 Genotype-phenotype relations
There is a strong inverse correlation between age of onset (AO) and expanded 
CAG repeat length. The length of the expanded CAG repeat accounts for about 70% 
Figure 1. 
Neuropathological changes in the HD brain.
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of the variation in AO, however, repeat size alone should not be used to predict AO 
[16]. The second modifying factor of AO is the sex-of-parent effect, which accounts 
for 2–5% of the variation. Juvenile HD patients more likely inherit the disease from 
their fathers, and patients with late AO more frequently inherit the disease from 
their affected mothers [16]. The remaining variation in AO may partly be explained 
by environmental effects, however, studies suggest a strong genetic component, 
which implies that there are other genes that modify AO in HD. New mutations, 
resulting in de novo disease presentation have been described in HD. Higher normal 
repeats may expand into the pathological range and may cause disease in the next 
generation, leading to a new mutation in the family.
2.3.4 Huntingtin mRNA and protein
IT-15 gene is expressed ubiquitously in all human tissues in the form of two 
major messenger RNA (mRNA) transcripts of 13.6 kb and 10.3 kb in length, which 
differ in the size of the 3’ UTR due to differential polyadenylation [17]. HD mRNA 
is expressed in both neural and non-neural tissues with high levels of expression in 
brain and testes [18].
The HD gene encodes a protein of 3144 amino acids with a molecular mass of 
348 kDa, termed huntingtin (htt). The polyQ tract starts at residue 18 and is fol-
lowed by a stretch of prolines. Protein studies also indicate ubiquitous expression of 
htt in various cells and tissues throughout the development and in the adult. In HD 
patients, normal and mutant huntingtin have a similar distribution and expression 
pattern [17, 18].
Huntingtin has no structural homology with other proteins, which makes the 
determination of its normal function difficult. The high degree of conservation 
across species suggests that the normal function of htt is essential. Studies of 
mice with targeted mutations that reduce the levels of htt to zero to 50 per cent 
reveal that htt also plays a critical role in embryogenesis, during brain develop-
ment. Reduced levels of htt lead to perinatal lethality and abnormalities in the 
head region, and significantly reduced levels produce a more severe phenotype, 
including abnormalities in skin, placement of the ear, and excencephaly. In addi-
tion, conditional knock-out mice develop a neurodegenerative disease [19]. HD 
cell models revealed that the wild type (wt) protein partially protects cells from 
mutant htt. Htt may also be important for cell survival through growth factor 
(GF) stimulation, as brain-derived neurotrophic factor-rescued cells express-
ing mutant htt [20]. In the neuron, htt is found throughout the cell body, and in 
axons, dendrites, and perikarya. Its association with microtubules and vesicles 
[21] has suggested a role in intracellular trafficking or neurotransmission, and 
retrograde transport. Association of htt with the cytoskeleton and cytosolic 
membrane suggests a role in normal cytoskeletal function [22]. Htt is also found 
in cytoplasmic inclusions in Alzheimer’s Disease (AD) and Parkinson’s Disease, 
which are mostly made up of cytoskeletal proteins. The presence of htt also in 
the nucleus could indicate that it may be involved in nuclear processes such as 
transcription, replication, RNA splicing, mRNA transport, and nuclear organiza-
tion. Huntingtin has no known homologies to any other protein, but it contains a 
few known sequence motifs with defined functions. Several proteins that interact 
directly with htt may give clues in understanding its possible functions. Based on 
their known functions, htt-interacting proteins can be grouped as proteins that 
are involved in gene transcription, intracellular signaling, trafficking, endocytosis 
or metabolism [23]. Analysis of the htt-interactors reveal that htt might function 
as a scaffold, controlling the proteins for signaling processes and intracellular 
transport [24].
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2.4 Molecular pathology in HD
The general flow of the molecular pathology in HD is summarized in Figure 2. 
It starts with gain of toxic function together with loss of normal htt upon confor-
mational change of the protein. The mutant protein aggregates and becomes more 
prone to proteolysis and the toxic htt fragment may interfere with transcription, 
leading to neuronal dysfuntion and selective neuronal death.
2.4.1 Gain and loss of function of Huntingtin
The general flow of the molecular pathology in HD is summarized in Figure 2. 
The molecular mechanism underlying polyQ pathogenesis has first been explained 
by toxic gain of function (GOF) of the mutant proteins. However, later findings 
strongly addressed loss of function of the normal proteins as a contributor to the 
disease process. In a mouse model, 146 CAG repeats were inserted into the HPRT 
gene, which is not involved in any CAG repeat disorder, in order to prove the gain 
of function mechanism. This mutant mice produced a polyQ expanded form of the 
HPRT protein and developed a late-onset neurological phenotype that resulted in 
death [5]. So, it is widely accepted that the polyQ mutations act by introducing a 
novel deleterious function to the mutant proteins. In humans, heterozygous inac-
tivation of htt by disrupting the HD gene does not result in HD phenotype [25]. In 
addition, mice that have only one functioning Hdh gene do not show any features of 
the disease [26]. Although an expanded CAG repeat could play a major role in the 
disease, the possibility of a dysfunction of the wt protein in HD cannot be ruled out. 
These findings suggest that the toxic effect of mutant htt might lie in sequestration 
of normal htt or of its functions [27].
2.4.2 Conformational change of the mutant Huntingtin
The baseline of the pathogenic mechanism causing HD appears to be the 
unusual conformation adopted by the mutant htt protein as a result of the expanded 
Figure 2. 
Molecular pathology of HD.
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polyQ segment. In a short protein fragment, the expanded polyQ tract facilitates 
aggregation, via conversion to an insoluble amyloid sheet structure [27]. Such a 
difference in the protein structure may lead to a change in the usual interactions of 
the protein and also may lead to abnormal interactions with other cellular factors. 
In addition, the mutant protein with an expanded polyQ tract may have effects on 
the function of the wild type protein. Two non-mutually exclusive mechanisms 
have been proposed to explain the aberrant conformation and subsequent aggrega-
tion of the mutant htt: Polar zipper and transglutaminase hypotheses. The polar 
zipper model states that the normal protein conformation is destabilized due to the 
presence of the expanded polyQ tract, and insolubleβ -pleated sheets may form 
and aggregate, by linkingβ -strands together via hydrogen bonding, forming “polar 
zipper” structures [28]. The transglutaminase hypothesis states that, mutant htt 
aggregation could be a result of the transglutaminase activity, which are normally 
involved in crosslinking of glutamine residues in different proteins. Huntingtin is 
a substrate of transglutaminase in vitro, and the rate of the reaction increases with 
the length of the polyQ tract [29]. According to these results, it can be hypothesized 
that, expanded polyQ stretch may result in increased crosslinking between mutant 
htt and other proteins, including itself, which may lead to aggregation.
2.4.3 Mutant protein aggregation
Transgenic mouse models of HD, expressing Exon 1 of the human HD gene 
with various CAG repeats numbers under the control of the human htt promoter, 
were established. These models served as a major step towards understanding the 
molecular pathology of HD. Mice expressing 18 CAG repeats developed normally 
and remained healthy. By contrast, mice that expressed 113 to 156 CAG repeats 
demonstrated progressive neurological symptoms and developed intraneuronal 
aggregates [21, 30]. Similar aggregates have been identified in post-mortem human 
cortical and striatal neurons and dystrophic neurites of HD brains [10]. Although 
NII occur in areas of pathology, their distribution does not correlate with the 
regions of neurodegeneration. In HD brains, inclusions contain truncated frag-
ments of the mutant htt, which are recognized only by antibodies to the N-terminal 
region of the htt. The intranuclear inclusions are spherical or elliptical, larger than 
the nucleoli, and are not isolated with a membrane. Electron microscopy reveals 
that the inclusions contain a mixture of granules, filaments and fibrils. Intranuclear 
aggregates are accepted as a common pathological marker for polyQ diseases, since 
similar structures are seen in all polyQ diseased brains. Since the inclusions are not 
isolated with a membrane, they can be regarded as membrane-less compartments 
or organelles. The membrane-less structures, in general, are important for vari-
ous essential functions in both the cytoplasm and the nucleus. They are formed 
through a phase separation process of RNA and protein molecules and are known 
to be responsive to the changes in the cellular environment. These structures are 
also dynamic, such that they can sequester or release proteins and RNA molecules, 
thereby affecting cellular stress response and neurodegenerative processes [31]. In 
this context, nuclear inclusions in HD should not be regarded as sole aggregates of 
mutant htt, but rather as a potential sink organelle for various RNA and proteins 
which possibly change the interactions of mutant htt and having deterministic roles 
in the fate of neurons with these inclusions and the neurodegenerative process in 
general.
Although accepted as a main pathological marker, the importance and function 
of the inclusions in cell culture models and HD brains are still not clear. Inclusions 
can be the primary cause of neuron loss, they can be beneficial by isolating the 
mutant protein from the rest of the cell, or just epiphenomenon. Since they appear 
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before the disease symptoms in the transgenic mice, a causal role has been sug-
gested [30]. In addition, inclusions well correlate with the size of the CAG repeats 
and susceptibility to cell death [32, 33]. Reduction of inclusions using heat shock 
protein HDJ-1 decreases cell death in vitro [34].
2.4.4 Proteolysis
Proteolysis of htt by caspases and calpains has been shown in several studies 
using cell culture, animal models and post-mortem analyses [35]. The toxic frag-
ment hypothesis suggests that, the pathological mechanism of HD may rely on 
the production of a toxic fragment containing the polyQ tract. The basal caspase 
activity may be sufficient to generate small amounts of cleavage products. If this 
cleavage products are toxic to neurons, then accumulation would put further stress 
to the cell, resulting in additional caspase activation in a positive feedback loop, and 
eventual cell death [36]. It is possible that over the life span of the affected individ-
ual, sufficient amounts of toxic polyQ fragments may be produced from this basal 
activity, pushing the balance toward cell death and neurodegeneration. The model 
for the role of caspases suggests two major stages. First, truncated htt fragments 
containing the expanded polyQ tract were produced by caspases (e.g. caspase-3, 
caspase-6), which can be considered as a rate-limiting step. Then, additional 
caspase activity (e.g. as caspase-8) can be provoked that may activate the caspases 
(e.g. caspase-3) further, which may eventually result in cell death.
2.4.5 Role of chaperones and proteasomes
Proteins with long polyQ tracts have altered conformation and are usually 
misfolded. Chaperone proteins help in the folding of proteins. Several heat shock 
proteins (HSP) function as modulators of protein folding, thereby prevent misfold-
ing and aggregation [37]. It was shown that HSP-40 and HSP-70 are sequestered 
in htt Exon 1 aggregates in cell models [38]. It is possible that redistribution into 
aggregates could deplete chaperones in the cells, preventing them to perform their 
functions.
Mutant polyQ protein aggregates were found to be ubiquitinated and associated 
with the proteasome apparatus. Cells tag misfolded proteins with ubiquitin, which 
directs them to proteasomes for degradation. In their abnormal conformations, 
mutant polyQ proteins might have a restricted entry into the proteolytic chamber 
or they might be incompletely degraded, causing jamming of the proteasomes. 
The depletion of proteasomal activity might lead to a build-up of many proteins 
normally cleared by proteasomes. Degradation of short-lived proteins is the major 
function of the proteasomes. The concentrations of some of these proteins, for 
example transcription factos, should be under strict control, since they are critical 
regulators of cellular homeostasis. If the proteasomal activity is impaired, the levels 
of short-lived proteins will rise abnormally, leading to cellular toxicity [39, 40].
2.4.6 Aggregates, nuclear localization and toxicity
Subcellular localization of the mutant polyQ proteins may be a more important 
determinant of toxicity, rather than the formation of aggregates. Although there is 
cytoplasmic pathology, many studies draw attention to the nucleus as the major site 
of pathogenesis. Transgenic mice, expressing expanded polyQ proteins with mutant 
nuclear localization signal (NLS) do not show disease pathology, and NLS-inserted 
polyQ proteins cause more toxicity in the cells. In addition, htt, being a cytoplas-
mic protein, was found in the nucleus when mutated. These findings support the 
Neurodegenerative Diseases - Molecular Mechanisms and Current Therapeutic Approaches
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hypothesis that nuclear localization of mutant polyQ proteins have an important 
role in disease pathogenesis [41]. Studies questioning aggregate toxicity and nuclear 
localization resulted in very important findings. When Q20 and Q42 peptides were 
subjected to cold shock, they formed fibrillar aggregates in the cells. When NLS was 
added to these peptides, aggregates entered into the nucleus, and both normal and 
mutated peptide aggregates resulted in cell death. However, cytoplasmic aggregates 
without NLS did not cause toxicity. Sixty five per cent of the cells with nuclear Q42 
aggregates exhibited cell death in 24 hours. According to these findings, subcellular 
localization of the aggregates, rather than the length of the polyQ stretch seems to 
be more important. When NLS is added to amyloid fibril forming bacterial CspB-1 
cold shock protein, aggregates are formed in the nucleus, but are not toxic. This 
proves that the polyQ tract itself is responsible for aggregate toxicity. Aggregate for-
mation requires a critical polyQ concentration, and this can explain the late disease 
onset and the negative correlation between the repeat length and AO. Proteins with 
polyQ repeats in the normal range are also shown to form fibrillar aggregates in 
vitro. However, proteins with normal numbers of repeats require a higher threshold 
concentration for protein aggregation, and the aggregate formation process is very 
slow, which makes this event impossible in a normal life span [33, 34, 41].
2.4.7 Transcriptional dysregulation
Cleavage and subsequent nuclear localization of polyQ proteins may result in 
changes in nuclear functions, like nuclear protein turnover, transcription, and RNA 
processing, through interactions with various nuclear factors. The most widely 
studied mechanism among them is the transcriptional dysregulation. One hypoth-
esis concerning transcriptional dysregulation is that polyQ proteins might normally 
interact with proteins in transcription complexes, and interactions might become 
aberrant when the polyQ is expanded [42]. Furthermore, mutant polyQ proteins 
can sequester other proteins containing polyQ stretches, like several transcription 
factors. Therefore, polyQ toxicity may arise from decreased availability of some 
transcription factors, resulting in abnormalities in the regulation of transcription. 
Htt was found to interact with proteins involved in transcriptional regulation, 
including transcriptional coactivators and corepressors. Mutant htt may be toxic 
through binding and depleting some of these factors. The most important TFs that 
are thought to be involved in HD pathogenesis are, CRE-binding protein (CREBP), 
p53, C-terminal binding protein (CtBP), TAFII 130 and Sp1 [43, 44].
2.4.8 Neuronal dysfunction and selective death in HD
The early disease process involves neuronal dysfunction rather than cell death, 
and in late stages apoptotic type of cell death occurs. Biochemical and immunohis-
tochemical studies show N-terminal htt fragments in brain tissues from affected HD 
patients and not from controls. Also, increased levels of DNA strand breaks in HD 
patient brains imply an apoptotic mechanism [10]. Although the mutated proteins 
are expressed in many cell types [18], a specific pattern of neuronal degeneration 
occurs in each polyQ disease [45]. The selective vulnerability of striatal and corti-
cal neurons in HD can not be explained by the level of htt expression, since other 
regions of the CNS express htt at the same level, but are not affected in the disease. 
Interactions of the polyQ containing proteins in specific cell types, sequestration 
of some tissue-specific transcription factors, or somatic increases in mutation size 
in the affected brain regions may provide an explanation. It is also possible that 
mutant proteins undergo cell type-specific proteolysis. Tissue-specific proteolysis 
can occur in two ways: Either the mutant proteins are processed with tissue specific 
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proteases, or the mutant protein in its new conformation becomes susceptible to 
different proteases. In fact, tissue-specific proteolysis has been demonstrated in one 
study, in which proteolysis specific to striatum and cortex was shown, without any 
differences between healthy and HD brain [46]. No striatum specific htt interactor 
has been identified yet in order to suggest a tissue-specific interaction of htt, but 
striatum-specific transcriptional regulators can be more sensitive to htt dysfunc-
tion, causing transcriptional dysregulation. On the other hand, N-terminal htt frag-
ments accumulate in striatal neurons and their axonal processes in HD transgenic 
mice. This finding supports the idea that mutant htt is proteolysed specifically and 
aggregates selectively in striatum [6].
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